Macromolecular Drugs

KY-0118

Dual functional IL2 fusion protein targeting PD-1 (Monotherapy)

Advanced solid tumors（Intravenous）

Phase I b

Phase I

Advanced solid tumors（Subcutaneous Drug Administration in the Lymphatic Drainage Area)

Phase I b 

KY-0301

MET-EGFR nanobispecific ADC

Advanced solid tumors (Lung cancer / head and neck cancer)

PhaseⅠ    

KY-0601

（double toxin)

B7H3-cMET nanobispecific ADC (FIC)

Advanced solid tumors (CRC/esophagus cancer)

  CMC       

KY-0901

(double toxin)

Bispecific nanobody drug conjugate with dual payloads (FIC)

Advanced solid tumors ( pancreatic cancer / cholangiocarcinoma, etc.

  PCC       

CAR-T

KQ-2003

BCMA×CD19

autologous CAR-T

rrMM

Phase Ⅱ

POEMS

Phase Ⅰ/Ⅱ a

rrMM

IND

rrMM

IND

KQ-2512

BCMA×CD19
in vivo CAR-T

Autoimmunedisease (SLE)

   PCC